Abstract. Blood 
Abstract. Blood flow was measured in the adenohypophysis and in the cerebral cortex of female F344 rats over a period of 90 min using the hydrogen clearance method. Tamoxifen, 1 mg/kg, administered iv reduced the blood flow in the adenohypophysis by 35%, whereas cerebral blood flow and arterial pressure remained unchanged. Seven days sc treatment with tamoxifen (1 mg/kg daily) had no demonstrable effect on blood flow. Anterior pituitary hyperplasia was induced in 15 rats with diethylstilbestrol containing implants. These rats responded to 7 days of sc tamoxifen treatment by 30% increase in adenohypophyseal blood flow. These results suggest that tamoxifen has a different effect on adenohypophysial circulation of the rat depending on whether it is administered in a low-or high-estrogen state.
Blood flow has long been shown to be closely re¬ lated to function in various endocrine glands (1) (2) (3) (4) including the adenohypophysis (5, 6) . Estrogens have been demonstrated to change blood flow both in reproductive tissue (7) and endocrine or¬ gans (8) . Tamoxifen (TAM) is a mixed estrogen agonist-antagonist. Its activity depends on the dose, the species, and the level of estrogen present when administered (9) (10) (11) . It is best known for its clinical use in the management of human breast cancer (12) , but it has been tried to enhance the ef¬ fects of bromocriptine in the treatment of prolactinomas (13) . The effects of TAM on the growth of human and estrogen-induced rat pituitary adeno¬ mas have been investigated both in vitro and in vivo (14, 15 (16, 17) . This technique is based on the finding that the rate of decline in partial pressure of hydrogen gas in a given tissue during desaturation is proportionai to the flow of blood through that tissue in the vicinity of the electrode (17) . The In the 15 rats of the third series, pituitary gland hyperplasia was induced using sc implantation of diethylstilbestrol containing capsules. The procedure was described elsewhere (18) . Such implants were estimated to release (ig/kg diethylstilbestrol (DES) daily. The implants were in situ for 10 (Fig. 1) .
Discussion
Changes of blood flow in endocrine glands are considered to be closely related to alterations in (7) and endocrine organs e.g. adrenal glands (8) even in acute admin¬ istration. Implantation of DES in slow-release silastic capsules leads to adenomatous hyperplasia in the anterior pituitary (21) and in parallel the blood flow in the gland progressively decreases (18, 22) , particularly in the centre (23) . The periphery of the pituitary gland received additional blood supply from newly-formed durai vessels (24, 25) which leads to an increase in total adenohypophysial blood flow (18) . The apparent discrepancy between the increased total blood flow and the reduced figure as expressed per unit weight of the gland is due to the drastic increase in size of the adenohy¬ pophysis in excess of the rate of increase in vascu¬ lar supply. When such DES pretreated rats have been given bromocriptine, the total adenohypo¬ physial blood flow has been shown to decrease to¬ wards the normal (26) . TAM had an opposite effect when given to rats bearing synthetic estrogen-containing capsules. TAM is known to act as an estrogen agonist and an¬ tagonist (27) depending not only on the target organ and the species (28) , but also on the endo¬ crine status of the subject (29, 30) . Tamoxifen and its major metabolite 4-hydroxytamoxifen (31) both have a lower intrinsic estrogen agonist activity than estradiol (32) . Thus the dual action can be ex¬ plained by the common receptor theory: the agon¬ ist or antagonist action of a low intrinsic activity compound is determined by the concentration of the high-activity compound on the receptor (11) .
Tamoxifen suppresses the growth of the es¬ trogen-dependent transplantable rat pituitary tu¬ mour 7315a (33), whereas spontaneously occurring transplantable prolactinomas show only a moder¬ ate response (34) . In estradiol-treated ACI rats TAM completely blocked the time-dependent in¬ crease of pituitary weight when it was given from the start together with the estrogen, but only a slight decrease was seen when the drug was in¬ itiated subsequent to the establishment of estrogen-induced hyperplasia (15) . In our material the DES-induced nodular hyperplasia was not reversed but enhanced when TAM was added over the tenth week of DES induction in female F344
rats. Blood flow per unit weight in the hyperplastic adenohypophysis was enhanced after one week of TAM treatment, thus in the presence of DES ta¬ moxifen had an opposite effect on adenohypo¬ physial circulation to that observed in normal rats. Moreover, in these animals the total adenohypo¬ physial blood flow was also increased after TAM which is the opposite response to that seen after administration of bromocriptine (26) .
On the basis of the observations on inhibition of growth in animal pituitary tumours it has been suggested in the past that studies should be under¬ taken with TAM treatment of human pituitary adenomas (34) . However, such inhibition was found mainly when TAM was given at the onset of tumour induction. We find it important that in our study where TAM was given after the adenomatous change was established (which is more similar to the clinical situation) not inhibition but enhanced growth and increased vascular supply was ob¬ served.
In conclusion, it appears that tamoxifen changes the blood flow in the adenohypophysis of female rats and the direction of the change is different de¬ pendent on the high-or low-estrogen state of the animal. It 
